Teleflex Incorporated (TFX) Position Trimmed by Rowland & Co. Investment Counsel ADV

Rowland & Co. Investment Counsel ADV reduced its position in Teleflex Incorporated (NYSE:TFX) by 4.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,137 shares of the medical technology company’s stock after selling 567 shares during the quarter. Rowland & Co. Investment Counsel ADV’s holdings in Teleflex were worth $2,790,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Toronto Dominion Bank increased its position in shares of Teleflex by 14.5% during the second quarter. Toronto Dominion Bank now owns 552 shares of the medical technology company’s stock worth $115,000 after acquiring an additional 70 shares during the period. Advisory Services Network LLC increased its position in shares of Teleflex by 933.8% during the second quarter. Advisory Services Network LLC now owns 827 shares of the medical technology company’s stock worth $172,000 after acquiring an additional 747 shares during the period. Cornerstone Capital Management Holdings LLC. purchased a new position in shares of Teleflex during the second quarter worth approximately $175,000. Coldstream Capital Management Inc. purchased a new position in shares of Teleflex during the third quarter worth approximately $226,000. Finally, Atalanta Sosnoff Capital LLC purchased a new position in shares of Teleflex during the fourth quarter worth approximately $280,000. 89.29% of the stock is currently owned by institutional investors.

Teleflex Incorporated (NYSE TFX) traded up $2.74 during midday trading on Thursday, hitting $260.66. 218,238 shares of the stock were exchanged, compared to its average volume of 229,142. The company has a current ratio of 4.72, a quick ratio of 3.70 and a debt-to-equity ratio of 0.88. Teleflex Incorporated has a 1 year low of $162.79 and a 1 year high of $271.23. The company has a market capitalization of $11,620.00, a P/E ratio of 47.05, a PEG ratio of 1.90 and a beta of 1.09.

Teleflex (NYSE:TFX) last released its quarterly earnings data on Thursday, November 2nd. The medical technology company reported $2.12 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.01 by $0.11. Teleflex had a net margin of 12.41% and a return on equity of 16.27%. The firm had revenue of $534.70 million for the quarter, compared to the consensus estimate of $522.94 million. During the same period last year, the firm earned $1.80 earnings per share. The company’s quarterly revenue was up 17.3% on a year-over-year basis. equities research analysts expect that Teleflex Incorporated will post 8.36 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, December 15th. Stockholders of record on Wednesday, November 15th were paid a dividend of $0.34 per share. The ex-dividend date of this dividend was Tuesday, November 14th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.52%. Teleflex’s dividend payout ratio is presently 24.55%.

In other news, CEO Benson Smith sold 2,000 shares of the stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $258.10, for a total transaction of $516,200.00. Following the transaction, the chief executive officer now directly owns 76,634 shares in the company, valued at $19,779,235.40. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Stephen K. M.D. Klasko sold 200 shares of the stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $265.32, for a total transaction of $53,064.00. Following the transaction, the director now owns 8,080 shares in the company, valued at $2,143,785.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,600 shares of company stock worth $666,492. Insiders own 2.39% of the company’s stock.

A number of brokerages have recently commented on TFX. Piper Jaffray Companies began coverage on shares of Teleflex in a research report on Friday, November 10th. They set an “overweight” rating and a $295.00 target price on the stock. Stephens reaffirmed a “buy” rating and set a $270.00 target price (up from $230.00) on shares of Teleflex in a research report on Monday, September 25th. Zacks Investment Research raised shares of Teleflex from a “hold” rating to a “buy” rating and set a $265.00 target price on the stock in a research report on Friday, September 22nd. ValuEngine lowered shares of Teleflex from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Finally, Needham & Company LLC raised their target price on shares of Teleflex from $237.00 to $285.00 and gave the stock a “buy” rating in a research report on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $274.44.

COPYRIGHT VIOLATION WARNING: “Teleflex Incorporated (TFX) Position Trimmed by Rowland & Co. Investment Counsel ADV” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/11/teleflex-incorporated-tfx-position-trimmed-by-rowland-co-investment-counsel-adv.html.

Teleflex Company Profile

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFX).

Institutional Ownership by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply